CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community ...
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors ...
SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been randomized in the pivotal Phase 3 CAREFNDR trial, a multicenter, ...
Gastric Cancer Diagnostics Market size was valued at US$ 3.5 Bn in 2024 and is projected to reach US$ 6.9 Bn by 2035, growing at a CAGR of 6.4% during 2025–2035.
CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics' commitment to addressing unmet needs in the neuroendocrine tumor community ...
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the best biotech stocks to buy according to Wall Street analysts. On ...
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the ...
The CALM-CAH Phase 3 study is a randomized, placebo-controlled trial evaluating atumelnant in adults with classic CAH, designed to assess reductions in excess androgens, improvements in glucocorticoid ...
Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients ...
PRRT retreatment may be well tolerated and confer a survival benefit in patients with well-differentiated, metastatic neuroendocrine tumors, a study suggests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback